Seeking Alpha

Street darling Pharmacyclics upgraded at Goldman

  • Goldman is out with some new estimates for Pharmacyclics' (PCYC) Ibrutinib.
  • Analyst Navdeep Singh sees a $5B opportunity in CLL and a $2.5B opportunity in MCL, WM, and DLBCL.
  • Singh's price target is upped to $170 (from $111), representing a 38% premium to Thursday's close.
  • Optimism surrounding Ibrutinib has reached a fever pitch, and some estimates peg the drug's potential as high as $9B.
  • PCYC +6.3% premarket.
Comments (1)
  • Janice214
    , contributor
    Comment (1) | Send Message
     
    I had non hodgkins follicular lymphoma and also am a nurse. I have been following pcyc since it was 6. I have said it will be 150 by Dec. This drug is changing the face of hematological diseases.
    11 Oct 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs